Switch theme
Sign up to access all valuation multiples
Dis-Chem Pharmacies Ltd is a pharmaceutical company based in South Africa. Its product portfolio includes personal care products, beauty products, healthcare and nutrition products, and dispensary and baby care products. The operating segments of the group are Retail and Wholesale. It derives maximum revenue from the Retail segment, which includes company stores, retailers of pharmaceuticals and a variety of health and beauty products, as well as pharma-logistic services and oncology and retailers of pharmaceutical products. The Wholesale segment consists of the CJ wholesale and company distribution businesses, wholesalers of pharmaceuticals, and a variety of health and beauty products. Geographically, the group carries out its business operations principally in South Africa.
1978
20.6K+
LTM Revenue $2.2B
LTM EBITDA $180M
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dis-Chem Pharmacies has a last 12-month revenue (LTM) of $2.2B and a last 12-month EBITDA of $180M.
In the most recent fiscal year, Dis-Chem Pharmacies achieved revenue of $2.2B and an EBITDA of $183M.
Dis-Chem Pharmacies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dis-Chem Pharmacies valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| Gross Profit | $547M | XXX | $489M | XXX | XXX | XXX |
| Gross Margin | 24% | XXX | 22% | XXX | XXX | XXX |
| EBITDA | $180M | XXX | $183M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| EBIT | $116M | XXX | $118M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $65.7M | XXX | $65.6M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $166M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Dis-Chem Pharmacies's stock price is ZAR 34 (or $2).
Dis-Chem Pharmacies has current market cap of ZAR 28.7B (or $1.6B), and EV of ZAR 34.4B (or $1.9B).
See Dis-Chem Pharmacies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $1.6B | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Dis-Chem Pharmacies has market cap of $1.6B and EV of $1.9B.
Dis-Chem Pharmacies's trades at 0.9x EV/Revenue multiple, and 10.6x EV/EBITDA.
Equity research analysts estimate Dis-Chem Pharmacies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dis-Chem Pharmacies has a P/E ratio of 24.3x.
See valuation multiples for Dis-Chem Pharmacies and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 10.6x | XXX | 10.6x | XXX | XXX | XXX |
| EV/EBIT | 16.5x | XXX | 16.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.3x | XXX | 25.0x | XXX | XXX | XXX |
| EV/FCF | 22.7x | XXX | -100.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDis-Chem Pharmacies's last 12 month revenue growth is 12%
Dis-Chem Pharmacies's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $18K for the same period.
Dis-Chem Pharmacies's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dis-Chem Pharmacies's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dis-Chem Pharmacies and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $18K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dis-Chem Pharmacies acquired XXX companies to date.
Last acquisition by Dis-Chem Pharmacies was XXXXXXXX, XXXXX XXXXX XXXXXX . Dis-Chem Pharmacies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dis-Chem Pharmacies founded? | Dis-Chem Pharmacies was founded in 1978. |
| Where is Dis-Chem Pharmacies headquartered? | Dis-Chem Pharmacies is headquartered in South Africa. |
| How many employees does Dis-Chem Pharmacies have? | As of today, Dis-Chem Pharmacies has 20.6K+ employees. |
| Who is the CEO of Dis-Chem Pharmacies? | Dis-Chem Pharmacies's CEO is Mr. Rui Manuel Morais. |
| Is Dis-Chem Pharmacies publicy listed? | Yes, Dis-Chem Pharmacies is a public company listed on JSE. |
| What is the stock symbol of Dis-Chem Pharmacies? | Dis-Chem Pharmacies trades under DCP ticker. |
| When did Dis-Chem Pharmacies go public? | Dis-Chem Pharmacies went public in 2016. |
| Who are competitors of Dis-Chem Pharmacies? | Similar companies to Dis-Chem Pharmacies include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Dis-Chem Pharmacies? | Dis-Chem Pharmacies's current market cap is $1.6B |
| What is the current revenue of Dis-Chem Pharmacies? | Dis-Chem Pharmacies's last 12 months revenue is $2.2B. |
| What is the current revenue growth of Dis-Chem Pharmacies? | Dis-Chem Pharmacies revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Dis-Chem Pharmacies? | Current revenue multiple of Dis-Chem Pharmacies is 0.9x. |
| Is Dis-Chem Pharmacies profitable? | Yes, Dis-Chem Pharmacies is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dis-Chem Pharmacies? | Dis-Chem Pharmacies's last 12 months EBITDA is $180M. |
| What is Dis-Chem Pharmacies's EBITDA margin? | Dis-Chem Pharmacies's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Dis-Chem Pharmacies? | Current EBITDA multiple of Dis-Chem Pharmacies is 10.6x. |
| What is the current FCF of Dis-Chem Pharmacies? | Dis-Chem Pharmacies's last 12 months FCF is $84.3M. |
| What is Dis-Chem Pharmacies's FCF margin? | Dis-Chem Pharmacies's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Dis-Chem Pharmacies? | Current FCF multiple of Dis-Chem Pharmacies is 22.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
